Overview
These calculators illustrate potential savings from selected changes in prescribing. Many of the examples shown involve relatively simple switches from one formulation to another, with no change in drug or total daily dose. Others show the savings that could be made from switching to effective alternatives from the same therapeutic class.
Frequency
Quarterly
Data period
September 2026
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in July 2026.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licences, significant new guidance, and decisions that have been made by recognised bodies.
This edition covers new and updated medicines and guidance published in July 2026.
This information is produced for use by NHS healthcare professionals.
This report looks at the top 50 BNF sections and drugs in terms of spend at ICB and SICBL level for the financial year to date with a focus on cost growth and item growth.
Frequency
Monthly
Data period
April to June 2026
Overview
This report provides headline financial information based on total prescribing for the whole BNF at ICB, sub-ICB and PCN level for the financial year to date with particular focus on cost and item growth compared to the same period from the previous financial year plus financial forecasting.
Frequency
Monthly
Data period
June 2026
The purpose of this report is to present the predicted cost impact of category A, M and C drug tariff PartVIIIA price changes on primary care spending. The data is calculated by matching the ePACT2 prescribing data for the latest month available to the current prices listed in the NHSBSA Drug Tariff PartVIIIA. An adjustment is also made if necessary to the prescribing data of each drug to account for any difference in dispensing days between the 2 months. Data is presented at SICBL and ICB level.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Quarterly
July 2026 (Drug Tariff), May 2026 (ePACT2 Prescribing data)
This report looks at prescribing trends in primary care for Drugs used in Diabetes at SICBL and ICB level with particular focus on insulins, anti-diabetic drugs and diagnostic & monitoring devices. Prescribing data is weighted with QOF registers, and also uses HES data to measure prescribing outcomes.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Quarterly
April 2023 to March 2026
These pdf reports summarise the headline information from the Monthly Financial Headlines, Top 50 BNF Sections and Drugs and Price Concessionary bulletin reports at SICBL, ICB, regional and national level. Copies of this report are available on request via nuth.nyrdtc.rxsupp@nhs.net.
A version of the report showing the data for the 7 commissioning regions with England selected as the focus is shown below.
April to May 2026
Monthly
This report looks at prescribing trends in primary care for the Respiratory System at SICBL and ICB level with particular focus on bronchodilators and corticosteroids. Prescribing data is weighted with QOF registers, and also uses HES data to measure prescribing to outcomes. The report also calculates the potential opportunity cost for respiratory drugs based on the NHS England Right Care indicators.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Quarterly
April 2023 to March 2026
This report looks at prescribing trends in primary care for the Cardiovascular System at SICBL and ICB level with particular focus on anticoagulants, antiplatelets and lipid-regulating. Prescribing data is weighted with QOF registers, and also uses HES data to measure prescribing to outcomes. The report also calculates the potential opportunity cost for cardiovascular drugs based on the NHS England Right Care indicators.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Quarterly
April 2023 to March 2026